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Background:Abciximab reduces major adverse cardiac events in patients with ST elevationmyocardial infarction
undergoing primary percutaneous coronary intervention (pPCI). Standard protocol is intravenous abciximab
bolus during PCI plus abciximab infusion for 12–18 h post pPCI. Intracoronary (IC) abciximab bolus administra-
tion results in high local drug concentrations and hence it should have higher antiplatelet effect. In this study, we
assess the short-term efﬁcacy and safety of IC compared to IV bolus of abciximab in ACS patients during pPCI.
Methods:Wecompared the clinical outcomes between the IC (n=56) and standard protocol (n=170) group of
patients. Primary endpoints included bleeding/vascular/ischemic complications and MACE.
Results: The two groups were similar with respect to baseline characteristics. IC abciximab bolus only reduced
bleeding complications, with no moderate bleed versus 7.2% in standard protocol group (p value 0.04).
Ischemic/vascular complications had statistically insigniﬁcant difference between the two groups.
Conclusion:We found no signiﬁcant difference between IC abciximab bolus only and standard abciximab therapy
in terms of ischemic/vascular complications and MACE. But there was higher risk of moderate bleed in standard
therapy group. The IC bolus route of abciximab may be superior to the intravenous route. Prospective random-
ized trials are warranted to validate these ﬁndings.
© 2014 TheAuthors. PublishedbyElsevier IrelandLtd.This is anopenaccessarticleunder theCCBY-NC-NDlicense
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Primary percutaneous coronary intervention (pPCI) is the ideal and
standard regimen in restoring epicardial perfusion in a ST-elevation
myocardial infarction (STEMI) [1]. Adjunctive therapy with glycopro-
tein IIb/IIIa receptor inhibitor (GPI) aims at coronary microcirculation
and improves the myocardial tissue perfusion which has considerable
prognostic impact [2,3]. There is robust data available in literature that
supports the beneﬁcial anti-ischemic effects of GPI use during PCI de-
creasing major adverse cardiac events (MACE) [4–6].
Intravenous abciximab is the standard route of administration, and
has been studied in various clinical trials. Standard protocol is intrave-
nous abciximab bolus during PCI plus abciximab infusion for 12–18 h
post pPCI. If given as an intracoronary (IC) bolus, it is expected to produce
high local concentrations at the PCI site with higher anti platelet action,
although at present clinical experience in the efﬁcacy of intracoronary
abciximab administration is limited [3,7–10]. Hence we are conducting
this study in order to compare the short-term efﬁcacy and safety of IC
compared to IV bolus of abciximab in ACS patients during pPCI.A, United States. Tel.: +1 413
).
and Ltd. This is an open access article u2. Methods
2.1. Patient population
The study was approved by our ethical and research committee. Pa-
tient consent for analysis of their data was standard. There were a total
of 170 patients in the standard therapy group versus 56 patients in IC
abciximab bolus only.
Inclusion criteria: We included all ACS patients who underwent PCI
from November 2007–December 2009 and received IC or IV bolus of
abciximab with the procedure.
Exclusion criteria: Patients who presented with cardiogenic shock,
those who could not get the drug due to any compelling contraindica-
tions or got GPI other than abciximab were excluded from the study
population.
2.2. Periprocedure pharmacology
All the patients got standard therapy for acute coronary syndrome
like aspirin (300 mg), clopidogrel (300–600 mg) and intravenous hep-
arin (60 units/kg) before they are wheeled to the cath lab, as per stan-
dard guidelines. Abciximab was given as 0.25 mg/kg bolus plus
0.125 μg/kg/min infusion for 12 h or 0.15–0.25 mg/kg IC bolus onlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Baseline clinical characteristics.
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abciximab bolus only or IV abciximab bolus plus infusion.Standard therapy
(n = 170)
IC bolus only
(n = 56)
p
Family history of premature
CAD (b50 years) (%)
38 (22.4) 13 (23.2) 0.89
Dyslipidemia (%) 122 (71.8) 22 (39.3) b0.01
Diabetes (%) 60 (35.3) 16 (28.6) 0.36
Hypertension (%) 87 (51.2) 30 (53.6) 0.76
Smoking (%) 62 (36.5) 22 (39.3) 0.71
Prior history of CHF (%) 6 (3.5) 2 (3.6) 0.98
Prior MI (%) 36 (21.2) 12 (21.4) 0.97
Cerebrovascular disease (%) 6 (3.5) 0 0.15
Peripheral vascular disease (%) 0 1 (1.8) 0.08
Previous CABG (%) 5 (2.9) 3 (5.4) 0.39
Previous PCI (%) 8 (4.7) 13 (23.2) b0.01
Medications
Aspirin (%) 170 (100) 54 (96.4) 0.06
Clopidogril (%) 156 (91.8) 54 (96.4) 0.38
Heparin (%) 139 (81.8) 45 (80.4) 0.81
Angina/NSTEMI/STEMI (%) 35 (22)/32 (20.1)/
92 (57.9)
5 (8.9)/10 (17.9)/
41 (73.2)
0.062.3. Study endpoints
Our primary endpoints were vascular, bleeding, ischemic complica-
tions and MACE as summarized in Table 1. Vascular complications in-
cluded pseudoaneurysm, arteriovenous ﬁstula, dissection and loss of
distal pulse. Bleeding complications were classiﬁed as major, moderate
and mild as per GUSTO classiﬁcation [11]. It included percutaneous
entry site bleeding and bleeding other than the entry site (e.g. retroper-
itoneal, gastrointestinal, genitourinary), diagnosed on clinical grounds
but conﬁrmed by further imaging.
Ischemic complications comprised of peri-procedural CK-MB eleva-
tion (≥3 times upper normal limit), acute or subacute stent thrombosis,
unplanned CABG and repeat target vessel revascularization.
MACE was the composite of death, urgent target vessel revasculari-
zation and periprocedural CK-MB elevation ≥3 times upper normal
limit. Data was retrieved from the ﬁles of the respective patients by
the research staff that was not related to the cardiac intervention.2.4. Statistical analysis
Statistical analysis was performed using SPSS 17. Percentages were
used to express categorical data and Chi-square test was used for com-
parison. Continuous variables were expressed as mean ± standard de-
viation and compared with Student t test. A p-value of ≤0.05 was
considered signiﬁcant.3. Results
3.1. Baseline clinical characteristics
They were similar in both the groups as reported in Table 2, however
there was a higher prevalence of dyslipidemia in bolus plus infusion
group (p b 0.01). Also more people had a history of prior PCI in the
bolus only group with statistical signiﬁcant p value. All the patients re-
ceived aspirin, clopidogrel and heparin in their initial emergency man-
agement. When we take a look at acute coronary syndrome distribution
between two groups, bolus only group has higher number of STEMI pa-
tients and standard therapy group mainly consists of unstable angina
andNSTEMI but p valuewas not signiﬁcant. All the variations in the base-
line characteristics were adjusted by using logistic regression.Table 3
Angiographic characteristics.
Standard therapy % IC bolus only % p-Value
Vessel disease3.2. Angiographic characteristics
Angiographic characteristics were almost the same in both the
groups as shown in Table 3. Except more patients in standard therapy
group achieved post PCI TIMI III ﬂow as compared to bolus only group
and probably it can be described by more high risk lesions in bolus
only group.Table 1
Study endpoints.
Vascular complications Pseudoaneurysm, AV ﬁstula, dissection, loss of distal pulse
Bleeding complications Mild, moderate and major
Ischemic complications Peri-procedural CK-MB elevation (≥3 times upper normal
limit), acute or subacute stent thrombosis, unplanned
CABG, repeat target vessel revascularization
MACE (major adverse
cardiac events)
Composite of death, urgent target vessel revascularization
and periprocedural CK-MB elevation ≥3 times upper normal
limit3.3. Vascular/bleeding complications
We found no difference in terms of vascular complications. But
when bleeding complications were stratiﬁed into major, moderate and
mild, we found that moderate bleed was higher in standard therapy
group as compared to bolus only group (p value= 0.04) as per Table 4.
3.4. Ischemic complication and MACE
Ischemic complications had statistically insigniﬁcant difference be-
tween the two groups. MACE for in hospital stay was the same in both
groups. Study endpoints summarized in Table 5.
4. Discussion
Glycoprotein IIb/IIIa receptors are present on the platelet surface
and mediate the ﬁnal common pathway of platelet aggregation, which
plays an important role in the formation of a platelet plug [12]. GPI
are potent platelet antagonists that inhibit aggregation of platelets at
the site of a disrupted plaque during PCI. There are three well known
GPI; abciximab, eptiﬁbatide and tiroﬁban. Some studies show that
eptiﬁbatide and tiroﬁban are non-inferior to abciximab and some
show abciximab is superior [13–15]. Most of the hospitals don't use
abciximab because of the cost issues [16].
In vitro studies have demonstrated that there is nearly complete sat-
uration of glycoprotein IIb/IIIa receptors with abciximab concentration
of 0.034 μmol/L, which corresponds to an IV bolus of 0.15 mg/kg. This
abciximab concentration inhibits 75% of the mechanical effects ofSingle vessel 48.9 43.8 0.76
Double vessel 37.8 46.9
Triple vessel 10.4 6.3
TIMI ﬂow
Pre I/II/III 13/8.4/46.6 12.5/3.1/34.4 0.24
Post I/II/III 1.5/9.9/88.5 3.1/9.4/81.3 0.03
Direct stenting 17.6 37.5 0.04
Aspiration device 30.2 31.3
PCI to graft 0.8 0 0.65
PCI to Nsingle vessel 0.1 0.01 0.54
Lesion risk
Low/medium/high 9.9/41.2/46.6 9.4/6.3/78.1 0.002
No reﬂow 6.9 3.1 0.11
Table 4
Vascular and bleeding complications.
Standard therapy
(n = 170)
IC bolus only
(n = 56)
p
Percutaneous entry site complications (%) 24 (21.6) 7 (12.5) .15
Bleeding (req. surgery/transfusion) (%) 16 (14.4) 6 (10.7) .50
Occlusion (%) 0 0
Loss of distal pulse (%) 5 (4.5) 0 .10
Dissection (%) 0 0
Pseudo-aneurysm (%) 1 (0.9) 1 (1.8) .62
AV-ﬁstula (%) 0 0
Peripheral embolization (%) 0 0
Infection (%) 3 (2.7) 0 .21
Thrombocytopenia (%) 4 (3.6) 3 (5.4) .60
Bleeding not related to percutaneous
entry site (%)
13 (11.7) 2 (3.6) .08
Retroperitoneal bleeding (%) 1 (0.9) 0 .48
Gastrointestinal bleeding (%) 6 (5.4) 1 (1.8) .27
Genital-Urinary bleeding (%) 4 (3.6) 1 (1.8) .51
Bleeding-other/unknown cause (%) 3 (2.7) 0 .21
Major bleed (%) 0 0
Moderate bleed (%) 8 (7.2) 0 .04
Mild bleed (%) 25 (22.5) 7 (12.5) .12
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small dose of local abciximab bolus is enough to achieve maximum
efﬁcacy.
The standard practice of GPI administration is, as an intravenous
bolus during the PCI procedure followed by a prolonged 12 to 18 h of in-
fusion [18,19]. The need for an infusion was established by the evalua-
tion of c7E3 (chimeric monoclonal-antibody Fab fragment directed
against the platelet glycoprotein IIb/IIIa receptor) for the prevention of
ischemic complications in EPIC trial which supported that the primary
composite endpoint death,myocardial infarction andurgent revascular-
ization reduced a greater degree in the arm with abciximab bolus
followed by a 12-hour infusion, compared with IV abciximab bolus-
only at 30 days and at late follow-up [18]. However bleeding complica-
tions were higher in the former group. We should consider the fact that
the EPIC trial was conducted during the percutaneous transluminal
coronary balloon angioplasty (PTCA) era, when threat of acute throm-
botic complications outweighed over the concerns of bleeding. With
the advent of stents and thienopyridine use, there has been a consider-
able decrease in the incidence of acute stent thrombosis.
In our study no difference was seen in stent thrombosis or other is-
chemic complications between the two groups. Also in hospital stay
MACE was statistically similar in both bolus and bolus plus infusion
arms, this is in accordance with Kini et al. [20], but literature does
show reduction of long term outcomes of death and MI in patients
who got intracoronary bolus of abciximab rather than the regular intra-
venous route [9].
In literature, decrease in vascular/bleeding complication was found
with bolus dosing versus infusion, [21] however in our study statistically
signiﬁcant difference was not found between the two groups, although
when, the variable, bleeding was stratiﬁed into major, moderate andTable 5
Study endpoints.
Standard therapy %
(n = 170)
IC bolus only %
(n = 56)
p-Value
Vascular complications 18.9 (21) 12.5 (7) 0.29
Bleeding complications 11.7 (13) 3.6 (2) 0.08
Periprocedural CK-MB elevation
N3× upper normal limit
67.9 (19) 74.5 (38) 0.52
Stent thrombosis 1.8 (2) 0 0.31
Urgent target vessel
revascularization
1.8 (2) 0 0.31
Death 3.6 (4) 3.6 (2) 0.98
MACE (in hospital stay) 71.9 (23) 75 (39) 0.75minor, reduction in moderate bleed was observed in the bolus only
group (p = 0.04).
Data advocates that IC bolus administration targets at the PCI site
precisely and therefore decrease the infarct size and improves micro-
vascular perfusion [3,21]. According to CICERO trial (N = 530) IC ad-
ministration of abciximab is associated with improved myocardial
reperfusion as assessed by myocardial blush grade and a smaller enzy-
matic infarct size [22]. This may be the reason that despite high-risk le-
sions (p b 0.01) in the bolus only groupwewere able to achieve post PCI
TIMI III ﬂow also seen by Romagnoli et al. [23].
Four meta-analysis studies comparing IC versus IV abciximab ad-
ministration in the setting of pPCI have been published recently and
all spreading a consistentmessage, showing superiority of IC over IV ad-
ministration of abciximab regarding clinical outcome further reinforc-
ing our results [24–31]. Holger Thiele and colleagues reported no
mortality difference between interventions in the AIDA STEMI trial
[24] but this randomized control trial has been criticized a lot with re-
spect to study methodology [32].
Also in some recent trials researchers concluded that abciximab
bolus only was associated with similar outcomes compared with bolus
followed by infusion [33,34] and it is of notice that in the new treatment
regimen there is not only a decrease in the dose of the bolus, but also in-
fusion is discontinued relative to the standard treatment strategy.More-
over, the route of administration is IC, which will provide high local
concentrations of abciximab at the PCI site. As mentioned above this
therapeutic range of bolus is adequate to inhibit maximum platelet ag-
gregation in order to produce the desired anti-platelet action. Therefore
by administering an appropriate dosage of bolus (according to the
weight of a patient) that lies within this therapeutic range, and not giv-
ing the infusion of abciximab we bring down the cost substantially
down which is one of the biggest hurdle towards using abciximab in
most of the hospital. Another big randomized trial (COCTAIL II) is on
its way, comparing IC bolus versus standard protocol, with the endpoint
of number of cross-sections with thrombus area more than 10% imme-
diately after stent implantation [35]. Hopefully this study will help us in
revising the protocol.5. Study limitations
It is a descriptive type of study. Another major limitation of this
study is the sample size of the bolus only group, because intracoronary
abciximab bolus dose is an emerging strategy.6. Conclusion
We found no signiﬁcant difference between IC abciximab bolus only
and standard abciximab therapy in terms of ischemic, vascular compli-
cations and MACE. But there was higher risk of moderate bleed in stan-
dard therapy group. Hence, adopting a bolus only GPI strategy via IC
route would not only provide the desired early protective anti-ischemic
action but also reduce the bleeding complications. The IC bolus route of
abciximab may be superior to the intravenous route. Prospective ran-
domized trials are warranted to validate these ﬁndings.References
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